HER-2 postive breast cancer

FDA grants ARX788 fast track designation for HER2-positive metastatic breast cancer
Pharmaceutical Business Review
Tue, 01/5/21 - 09:57 am
Ambrx
FDA
ARX788
HER-2 postive breast cancer
fast tack
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Motley Fool
Thu, 02/13/20 - 11:29 pm
Seattle Genetics
tucatinib
FDA
priority review
breast cancer
HER-2 postive breast cancer
ASCO 2019 – Macrogenics builds a case for margetuximab
EP Vantage
Wed, 06/5/19 - 09:37 am
Macrogenics
margetuximab
HER-2 postive breast cancer
Roche's breast cancer hopes get a boost from post-surgery Kadcyla approval
Fierce Pharma
Mon, 05/6/19 - 11:46 am
FDA
Roche
Kadcyla
HER-2 postive breast cancer
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
Motley Fool
Wed, 04/12/17 - 10:33 am
Roche
Tecentriq
Perjeta
HER-2 postive breast cancer
Ocrevus
MS
multiple sclerosis
diagnostics
generics
biosimilars
Pfizer breast cancer drug gets early FDA approval
Yahoo/AP
Wed, 02/4/15 - 09:07 am
Pfizer
palbociclib
HER-2 postive breast cancer
breast cancer
FDA
Merrimack announces clinical data from Phase 1 study of MM-302
The Fly on the Wall
Fri, 12/13/13 - 10:22 am
MM-302
Merrimack Pharmaceuticals
HER-2 postive breast cancer
Avastin Misses Mark Again in Breast Cancer
MedPage Today
Thu, 12/12/13 - 11:15 am
Avastin
Roche
HER-2 postive breast cancer